Language
English
Publication Date
1-1-2026
Journal
Annual Review of Medicine
DOI
10.1146/annurev-med-050224-121037
PMID
41592928
Abstract
Peanut allergy is a significant rising public health problem affecting both children and adults. Early peanut introduction has been adopted in multiple westernized nations as a preventative strategic measure to reduce the risk of developing peanut allergy, although implementation faces barriers. Multiple therapies to treat peanut allergy have been developed, including oral immunotherapy and omalizumab as approved treatments to provide protection against reactions from accidental exposure and reduce the risk of anaphylaxis, offering options beyond strict avoidance. Strategies in the developmental pipeline include epicutaneous immunotherapy and sublingual immunotherapy. The future is bright for individuals with peanut allergy, as these breakthroughs can help address the fear, uncertainty, severity, and lack of protection that has become synonymous with this disease. Shared decision-making is needed to ensure that each patient receives the management approach best suited to their needs, preferences, and goals.
Keywords
Humans, Peanut Hypersensitivity, Desensitization, Immunologic, Anaphylaxis, Omalizumab, Arachis, Anti-Allergic Agents, anaphylaxis, anti-IgE, epicutaneous immunotherapy, omalizumab, oral immunotherapy, peanut allergy, sublingual immunotherapy
Published Open-Access
yes
Recommended Citation
S Shahzad Mustafa, Aikaterini Anagnostou, and Matthew Greenhawt, "Updates in the Management of Peanut Allergy" (2026). Faculty, Staff and Students Publications. 7665.
https://digitalcommons.library.tmc.edu/baylor_docs/7665